Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from COSCIENS Biopharma ( (TSE:CSCI) ).
COSCIENS Biopharma Inc. reported a 35.2% increase in revenues for 2024, reaching $9.6 million, and ended the year with $16.4 million in cash. The company has stopped investing in certain pre-clinical programs following negative trial results and is focusing on natural-based products to drive future growth. Key developments include successful Phase 1 results for Avenanthramides Tablets, the launch of a new cosmeceutical website, and plans to commercialize new nutraceutical products in 2025. The company is also advancing its PGX technology for scalable production of biopolymers.
More about COSCIENS Biopharma
COSCIENS Biopharma Inc. is a life science company that develops and commercializes a diverse portfolio of cosmeceutical, nutraceutical, and pharmaceutical products. The company is focused on natural-based products and has recently undergone a strategic repositioning to streamline operations and prioritize its product pipeline.
YTD Price Performance: -10.26%
Average Trading Volume: 24,335
Technical Sentiment Signal: Strong Buy
Current Market Cap: $7.77M
Learn more about CSCI stock on TipRanks’ Stock Analysis page.